Novartis registers Phase IIIb trial of zigakibart + atrasentan in primary IgA nephropathy
This study was first posted on ClinicalTrials.gov on September 30, 2026. The trial plans to enroll 340 participants and plans to start December 1, 2026.
Primary source
ClinicalTrials.gov registry record, September 30, 2026
A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy
Read the source: A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation